Ricerca Biosciences appoints drug safety director
Douglas Fuhrer has right skills to guide preclinical drug development strategy
Fuhrer has more than 12 years of experience directing teams of scientists and technicians in large pharmaceutical companies, biotech organisations and CROs. His training and experience includes applied animal investigation skills, serving as a study director of toxicology and safety pharmacology Good Laboratory Practice (GLP) studies and completing multiple INDs and non-clinical programmes supporting clinical development. His expertise lies within many therapeutic areas including anti-infectives, cancer, immune regulation, diabetes, CNS, prostate enlargement and hepatitis C.
‘Doug possesses the experience and insights necessary to guide our preclinical drug development strategies,’ said Michael Placke, senior vice president and general manager of Ricerca’s Concord, Ohio, drug development operations.
You may also like
Manufacturing
Continuous innovation: redefining the future of pharmaceutical manufacturing
In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced